Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other financing activities (2016 - 2019)

Sangamo Therapeutics has reported Other financing activities over the past 4 years, most recently at $216000.0 for Q1 2019.

  • Quarterly results put Other financing activities at $216000.0 for Q1 2019, down 97.96% from a year ago — trailing twelve months through Sep 2021 was $216000.0 (down 99.16% YoY), and the annual figure for FY2021 was $943000.0, changed.
  • Other financing activities for Q1 2019 was $216000.0 at Sangamo Therapeutics, down from $10.6 million in the prior quarter.
  • Over the last five years, Other financing activities for SGMO hit a ceiling of $15.0 million in Q4 2017 and a floor of -$1.0 million in Q4 2016.
  • Median Other financing activities over the past 4 years was $5.4 million (2018), compared with a mean of $6.2 million.
  • Biggest five-year swings in Other financing activities: surged 1580.59% in 2017 and later tumbled 97.96% in 2019.
  • Sangamo Therapeutics' Other financing activities stood at -$1.0 million in 2016, then surged by 1580.59% to $15.0 million in 2017, then dropped by 29.57% to $10.6 million in 2018, then tumbled by 97.96% to $216000.0 in 2019.
  • The last three reported values for Other financing activities were $216000.0 (Q1 2019), $10.6 million (Q1 2018), and $15.0 million (Q4 2017) per Business Quant data.